U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07119918) titled 'PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis' on Aug. 06.
Brief Summary: An investigator-initiated, prospective, multicenter, randomized, double-blind, placebo-controlled trial comparing the 1-year incidence of stroke in patients with AIS or TIA within 7 days who are treated with either placebo or Recaticimab.
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Symptomatic Intracranial Atherosclerotic Stenosis
Intervention:
DRUG: Recaticimab
Recaticimab 300mg subcutaneous Q8W for 1 year.
DRUG: Placebo
Matched placebo subcutaneous Q8W for 1 year.
Recruitment Status: NOT_YET_RECRUITING
...